Summary
One of the main goals of the project is to sign a commercialisation agreement on CDNF to ensure its development will continue immediately from the TreatER project to late stage clinical development. Negotiations toward such agreement are confidential business information of Herantis however the outcome shall be published if such an agreement is reached.
More information & hyperlinks